Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Rating) Director Sangeeta N. Bhatia sold 621 shares of the business’s stock in a transaction that occurred on Friday, July 29th. The shares were sold at an average price of $278.77, for a total value of $173,116.17. Following the completion of the sale, the director now directly owns 5,282 shares of the company’s stock, valued at approximately $1,472,463.14. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
Vertex Pharmaceuticals Stock Performance
Shares of NASDAQ VRTX opened at $275.03 on Thursday. The business has a fifty day simple moving average of $277.11 and a 200 day simple moving average of $260.16. The company has a current ratio of 4.75, a quick ratio of 4.60 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $70.34 billion, a price-to-earnings ratio of 28.95, a PEG ratio of 2.02 and a beta of 0.45. Vertex Pharmaceuticals Incorporated has a one year low of $176.36 and a one year high of $296.84.
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Rating) last issued its earnings results on Thursday, May 5th. The pharmaceutical company reported $3.16 EPS for the quarter, missing analysts’ consensus estimates of $3.17 by ($0.01). The firm had revenue of $2.10 billion during the quarter, compared to analyst estimates of $2.07 billion. Vertex Pharmaceuticals had a net margin of 30.84% and a return on equity of 32.24%. The business’s revenue for the quarter was up 21.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.54 earnings per share. Sell-side analysts expect that Vertex Pharmaceuticals Incorporated will post 12.41 EPS for the current year.
Analyst Upgrades and Downgrades
Institutional Trading of Vertex Pharmaceuticals
Large investors have recently bought and sold shares of the stock. JJJ Advisors Inc. grew its position in Vertex Pharmaceuticals by 101.5% in the fourth quarter. JJJ Advisors Inc. now owns 133 shares of the pharmaceutical company’s stock valued at $29,000 after acquiring an additional 67 shares during the period. Trustcore Financial Services LLC grew its holdings in shares of Vertex Pharmaceuticals by 53.8% during the fourth quarter. Trustcore Financial Services LLC now owns 143 shares of the pharmaceutical company’s stock worth $31,000 after purchasing an additional 50 shares during the last quarter. TFC Financial Management grew its holdings in shares of Vertex Pharmaceuticals by 58.0% during the second quarter. TFC Financial Management now owns 109 shares of the pharmaceutical company’s stock worth $31,000 after purchasing an additional 40 shares during the last quarter. Crewe Advisors LLC bought a new stake in shares of Vertex Pharmaceuticals during the fourth quarter worth $32,000. Finally, Sittner & Nelson LLC grew its holdings in shares of Vertex Pharmaceuticals by 66.7% during the first quarter. Sittner & Nelson LLC now owns 125 shares of the pharmaceutical company’s stock worth $33,000 after purchasing an additional 50 shares during the last quarter. 89.84% of the stock is currently owned by institutional investors.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.
- Get a free copy of the StockNews.com research report on Vertex Pharmaceuticals (VRTX)
- Is it Time to Tap Molson Coors or Will Beer Sales Turn Flat?
- There Are Different Types of Stock To Invest In
- PayPal Continues To Struggle As Competition Increases
- Two High-Yield Deep-Values You Shouldn’t Ignore
- Is Starbucks Shooting For The Moon?
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.